Mithilesh Das, MD
Cardiovascular Disease · Indianapolis, INNPI 1568426443
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,550 of the $60,060 with a category attached, or 74.2%. Medical Device Business Services, Inc. accounts for 62.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $20,199 and has fallen 69.6% since, to $6,132 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $333.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$37K
- Medtronic$7K
- Biosense Webster, Inc.$7K
- Abbott$6K
- Boston Scientific$2K
- Cardiva Medical, Inc.$382
- plus $668 from 9 others
Across 28 payments — averaging $2427.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$45K
- Medtronic$16K
- Abbott$8K
What the payments were for
- Consulting fees$44,55074%
- Speaking & faculty fees$3,9006%
- Travel & lodging$5,6349%
- Food & beverage$5,97610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 22 | $37,350 |
| Medtronic(2 entities) | 38 | $7,090 |
| Biosense Webster, Inc. | 11 | $6,513 |
| Abbott | 56 | $6,152 |
| Boston Scientific | 26 | $1,905 |
| Cardiva Medical, Inc. | 9 | $382 |
| Johnson & Johnson | 2 | $151 |
| Volta Medical Inc | 1 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $102 |
| Biosig Technologies, Inc. | 1 | $86 |
| Pfizer | 5 | $83 |
| Atricure, Inc. | 1 | $47 |
| AstraZeneca | 1 | $43 |
| Boehringer Ingelheim | 1 | $23 |
| Convatec Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$43,670
- AVEIR$3,280
- Accent Pacemaker$1,000
- EVERA MRI XT DR SURESCAN$878
- Micra$264
- Cardiva VASCADE MVP VVCS 6-12F$251
- Quadra Assura CRT Defibrillator$176
- ALLURE$162
- COBALT DR MRI SURESCAN$151
- AMPLATZER AMULET$149
- Farapulse$137
- Confirm Rx$126
- XARELTO$121
- Carto 3 System$119
- VX1$116
- RHYTHMIA$116
- WATCHMAN FLX$102
How this compares
$60,060 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 301 | $345,863 |
| XareltoRivaroxaban | 47 | $56,987 |
| MultaqDronedarone Hcl | 11 | $22,076 |
| Metoprolol Succinate | 206 | $2,991 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 26 | $2,375 |
| SotalolSotalol Hcl | 63 | $1,848 |
| Midodrine Hcl | 16 | $1,811 |
| Flecainide Acetate | 35 | $1,435 |
| Potassium Chloride | 39 | $1,310 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 40 | $1,229 |
| Dofetilide | 11 | $1,222 |
| Amiodarone Hcl | 60 | $947 |
| Warfarin Sodium | 45 | $570 |
| Torsemide | 24 | $551 |
| Furosemide | 70 | $477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $83 | $345,863301 claims |
| Johnson & JohnsonXarelto | $151 | $56,98747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- Richard KovacsIndianapolis$136K
- George LolayIndianapolis$128K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.